Oncolytics Biotech Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Oncolytics Biotech de winst en omzet met respectievelijk 41.4% en 68.4% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 47.1% per jaar.

Belangrijke informatie

41.4%

Groei van de winst

47.1%

Groei van de winst per aandeel

Biotechs winstgroei	36.7%
Inkomstengroei	68.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	20 Sep 2024

Recente toekomstige groei-updates

Recent updates

Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

Apr 15

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Dec 31

Winst- en omzetgroeiprognoses

TSX:ONC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CAD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	9	-41	-72	-66	5
12/31/2025	1	-42	-86	-49	7
12/31/2024	N/A	-32	-48	-34	7
6/30/2024	N/A	-28	-27	-26	N/A
3/31/2024	N/A	-28	-28	-28	N/A
12/31/2023	N/A	-28	-28	-28	N/A
9/30/2023	N/A	-32	-28	-28	N/A
6/30/2023	N/A	-27	-26	-26	N/A
3/31/2023	N/A	-24	-25	-25	N/A
12/31/2022	N/A	-25	-23	-23	N/A
9/30/2022	N/A	-24	-24	-24	N/A
6/30/2022	N/A	-24	-24	-23	N/A
3/31/2022	N/A	-27	-23	-23	N/A
12/31/2021	N/A	-26	-23	-22	N/A
9/30/2021	N/A	-28	-22	-22	N/A
6/30/2021	N/A	-30	-24	-24	N/A
3/31/2021	N/A	-29	-24	-24	N/A
12/31/2020	N/A	-23	-22	-22	N/A
9/30/2020	N/A	-33	-24	-24	N/A
6/30/2020	N/A	-29	-22	-22	N/A
3/31/2020	N/A	-28	-20	-20	N/A
12/31/2019	N/A	-33	-20	-20	N/A
9/30/2019	N/A	-19	-17	-17	N/A
6/30/2019	N/A	-18	-16	-16	N/A
3/31/2019	N/A	-17	-11	-11	N/A
12/31/2018	N/A	-17	-12	-12	N/A
9/30/2018	N/A	-17	-11	-11	N/A
6/30/2018	N/A	-17	-11	-10	N/A
3/31/2018	N/A	-17	N/A	-16	N/A
12/31/2017	N/A	-16	N/A	-15	N/A
9/30/2017	N/A	-16	N/A	-15	N/A
6/30/2017	N/A	-16	N/A	-15	N/A
3/31/2017	N/A	-15	N/A	-13	N/A
12/31/2016	N/A	-15	N/A	-12	N/A
9/30/2016	N/A	-13	N/A	-13	N/A
6/30/2016	N/A	-13	N/A	-13	N/A
3/31/2016	N/A	-14	N/A	-15	N/A
12/31/2015	N/A	-14	N/A	-15	N/A
9/30/2015	N/A	-14	N/A	-14	N/A
6/30/2015	N/A	-16	N/A	-16	N/A
3/31/2015	N/A	-17	N/A	-16	N/A
12/31/2014	N/A	-19	N/A	-20	N/A
9/30/2014	N/A	-21	N/A	-21	N/A
6/30/2014	N/A	-22	N/A	-23	N/A
3/31/2014	N/A	-22	N/A	-22	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ONC de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ONC de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ONC de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ONC ( 68.4% per jaar) zal naar verwachting sneller groeien dan de markt Canadian ( 6.9% per jaar).

Hoge groei-inkomsten: De omzet van ONC ( 68.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ONC naar verwachting over 3 jaar hoog zal zijn

Oncolytics Biotech Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 23% to CA$5.83

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to CA$0.43 loss

Consensus EPS estimates fall by 20%

Price target decreased by 14% to CA$6.50

Price target decreased to CA$6.21

Recent updates

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

Price target decreased by 23% to CA$5.83

New minor risk - Profitability

Oncolytics Biotech Inc., Annual General Meeting, May 15, 2024

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

New minor risk - Profitability

Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors

Forecast to breakeven in 2026

New minor risk - Market cap size

Oncolytics Biotech Inc. Announces the Anal Cancer Cohort of the Goblet Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Oncolytics Biotech Inc. Presents Further Positive Pelareorep Translational Data At SITC

Oncolytics Biotech Inc. Announces Poster Presentation of Positive, Updated Results from the Phase 1/2 GOBLET Study

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the Goblet Study

Oncolytics Biotech Inc. Unveils Results from Its Phase 2 Trial of A Drug for Metastatic Breast Cancer

Oncolytics Biotech Inc. has completed a Composite Units Offering in the amount of $15.00075 million.

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Oncolytics Biotech Inc. Announces Selection of Pelareorep for Inclusion as New Investigational Treatment in Precision Promise, an Innovative Adaptive Phase 3 Clinical Trial

New minor risk - Market cap size

Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Oncolytics Biotech Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives 50% Improvements in ORR and mPFS

Consensus EPS estimates upgraded to CA$0.43 loss

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 20%

Price target decreased by 14% to CA$6.50

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?

Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting

Price target decreased to CA$6.21

Oncolytics Biotech(R) Appoints Jonathan Rigby to Its Board of Directors

We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

Oncolytics Biotech Inc. Appoints James T. Parsons to its Board of Directors

Independent Director recently bought CA$56k worth of stock

Consensus forecasts updated

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

Oncolytics Biotech Inc. Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with Chimeric Antigen Receptor T Cell Therapy in Solid Tumors

Oncolytics Biotech Inc. Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting

Oncolytics Biotech Inc., Annual General Meeting, Jun 16, 2022

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of Its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech Inc. Promotes Thomas C. Heineman to Chief Medical Officer

No longer forecast to breakeven

Oncolytics Biotech® Inc. Provides Positive Safety Update on Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech® Inc. Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Oncolytics Biotech Inc. Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

No longer forecast to breakeven

Oncolytics Biotech Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy

No longer forecast to breakeven

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-Of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

Oncolytics Biotech Inc., Annual General Meeting, May 07, 2021

Oncolytics Biotech Inc. Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors

Price target raised to CA$10.13

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

New 90-day high: CA$3.40

Oncolytics Biotech Announces Positive Clinical Results against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting

Oncolytics Biotech® Inc. and Solti-Innovative Breast Cancer Research Announce the Publication of an Electronic Poster with Clinical Data from the Aware-1 Window-Of-Opportunity Breast Cancer Study At the Society for Immunotherapy of Cancer

Oncolytics Biotech Inc. Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor

New 90-day high: CA$3.00

Oncolytics Biotech Inc. Appoints Richard Vile, Ph.D., to Its Scientific Advisory Board

New 90-day low - CA$2.14

Price target lowered to CA$7.51

New 90-day low - CA$2.46